Iron stores are associated with asymptomatic atherosclerosis in healthy men of primary prevention

European Journal of Clinical Investigation

Volumn 41, Issue 8, 2011, Pages 846-853

  Syrovatka, Petr ^a,b   Kraml, Pavel ^b   Hulikova, Katarina ^b   Fialova, Lenka ^b   Vejrazka, Martin ^b   Crkovska, Jirina ^b   Potockova, Jana ^b   Andel, Michal ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atherosclerosis; Endothelial dysfunction; Ferritin; Oxidative stress; Transferrin

Indexed keywords

CD163 ANTIGEN; FERRITIN; FIBRINOGEN; HEMOGLOBIN; INTERLEUKIN 8; SOLUBLE CLUSTER OF DIFFERENTIATION 163; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ASYMPTOMATIC DISEASE; CAROTID ATHEROSCLEROSIS; COMMON CAROTID ARTERY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; IRON STORAGE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FERRITINS; FIBRINOGEN; HUMANS; INTERLEUKIN-8; IRON; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; RECEPTORS, TRANSFERRIN; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 79960093245     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02474.x     Document Type: Article

References (34)

1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
2. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
3. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300-7.
4. Tuomainen TP, Salonen R, Nyyssönen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2, 682 men in eastern Finland. BMJ 1997;314:793-4.
5. Ascherio A, Willet WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation 1994;89:969-74.
6. Stampfer MJ, Grodstein F, Rosenberg I, Willett W, Hennekens C. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Circulation 1993;87:688.
7. Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1995;141:719-23.
8. Awiram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993;98:1-9.
9. Tuomainen NP, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1, 013 eastern Finnish men. Diabetes Care 1997;20:426-8.
10. Fernández-Real JM, Ricart-Engel W, Arroyo E, Balançá R, Casamitjana-Abella R, Cabrero D et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-8.
11. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanetz H et al. A molecular basis for insulin resistance: elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;272:29911-8.
12. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003;52:1-8.
13. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007;7:1926-33.
14. Tuomainen TP, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461-6.
15. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2.
16. Witko-Sarsat V, Friedlander M, Capeillere-Blandin CH, Nguyen-Khoa T, Nguyen AT, Zingraff J et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
18. Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A et al. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 2004;35:453-7.
19. Mascitelli L, Pezzetta F, Goldstein MR. Iron, metabolic syndrome, nonalcoholic fatty liver disease and carotid atherosclerosis. Atherosclerosis 2008;205:39-40.
20. Li W, Xu LH, Forssell C, Sullivan JL, Yuan XM. Overexpression of transferin receptor and ferritin related to clinical symptoms and destabilization of human carotid plaques. Exp Biol Med 2008;233:818-26.
21. Mainous AG 3rd, Wells BJ, Everett CJ, Gill JM, King DE. Association of ferritin and lipids with C-reactive protein. Am J Cardiol 2004;93:559-62.
22. Mauriello A, Sangiorgi G, Palmieri G, Virmani R, Holmes DR Jr, Schwartz RS et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation 2000;101:744-50.
23. Sabeti S, Exner M, Mlekusch W, Amighi J, Quehenberger P, Rumpold H et al. Prognostic impact of fibrinogen in carotid atherosclerosis nonspecific indicator of inflammation or independent predictor of disease progression? Stroke 2005;36:1400-4.
24. Devendra GP, Hart SA, Whitney EJ, Krasuski RA. Impact of Fibrinogen Levels on Angiographic Progression and 12-Year Survival in the Armed Forces Regression Study. Angiology 2010;61:333-7.
25. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
26. Miura K, Nagakawa H, Ueshima H, Okayama A, Saitoh S, Curb JD et al. Dietary factors related to higher plasma fibrinogen levels in Japanese-Americans in Hawaii compared with Japanese in Japan. Arterioscler Thromb Vasc Biol 2006;26:1674-9.
27. Davis BH, Zarev PV. Human monocyte sCD163 expression inversely correlates with soluble sCD163 plasma levels. Cytometry B Clin Cytom 2005;63:16-22.
28. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 2006;99:943-50.
29. Abraham NG, Drummond G. CD163-Mediated hemoglobin-heme uptake activates macrophage HO-1, providing an antiinflammatory function. Circ Res 2006;99:911-4.
30. Moestrup SK, Möller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004;36:347-54.
31. Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 2002;526:93-6.
32. Aristoteli LP, Möller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble sCD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006;184:342-7.
33. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res 2009;84:353-60.
34. Herder C, Baumert J, Thorand B, Martin S, Löwel H, Kolb H et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006;26:2147-52.